Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...

Francis Medical, developing water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced ...

In this interview with Dr. Maria de Miguel, we explore the transformative potential of Antibody-Drug Conjugates (ADCs) in ...

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a ...

IMUNON announced that its new DNA-based immunotherapy for advanced ovarian cancer has shown encouraging results in the ongoing OVATION 2 trial. The treatment, known as IMNN-001, reportedly boosts leve ...

AI is evolving fast and life sciences is feeling the impact. In 2025, its role will expand even further, driving efficiencies and accelerating discoveries. The industry has already seen what AI can do ...

Bayer continues to form new partnerships to expand its targets for cancer treatment, recently collaborating with MOMA and NextRNA, two pioneers in oncology innovation. In this exclusive interview, Dr.

New data for darolutamide confirm safety and improved efficacy across subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) by 40% and 70% respectively, compared to placebo ...